3FJ6

Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 2

3FJ6 の概要

• エントリーDOI: 10.2210/pdb3fj6/pdb
• 関連するPDBエントリー: 3F1Q 3FJL
• 分子名称: Dihydroorotate dehydrogenase, OROTIC ACID, FLAVIN MONONUCLEOTIDE, ... (7 entities in total)
• 機能のキーワード: alpha-beta barrel tim barrel, fad, flavoprotein, membrane, mitochondrion, mitochondrion inner membrane, oxidoreductase, polymorphism, pyrimidine biosynthesis, transit peptide
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Mitochondrion inner membrane; Single-pass membrane protein: Q02127
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 41030.32

構造登録者

Heikkila, T. (登録日: 2008-12-14, 公開日: 2009-06-09, 最終更新日: 2023-11-01)

主引用文献

Davies, M.,Heikkila, T.,McConkey, G.A.,Fishwick, C.W.G.,Parsons, M.R.,Johnson, A.P.
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases
J.Med.Chem., 52:2683-2693, 2009

PubMed Abstract: Pyrimidine biosynthesis is an attractive drug target in a variety of organisms, including humans and the malaria parasite Plasmodium falciparum. Dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention. In this study, we have applied SPROUT-LeadOpt, a software package for structure-based drug discovery and lead optimization, to improve the binding of the active metabolite of the anti-inflammatory drug leflunomide to the target cavities of the P. falciparum and human dihydroorotate dehydrogenases. Following synthesis of a library of compounds based upon the SPROUT-optimized molecular scaffolds, a series of inhibitors generally showing good inhibitory activity was obtained, in keeping with the SPROUT-LeadOpt predictions. Furthermore, cocrystal structures of five of these SPROUT-designed inhibitors bound in the ubiquinone binding cavity of the human dihydroorotate dehydrogenase are also analyzed.

PubMed: 19351152
DOI: 10.1021/jm800963t

実験手法

X-RAY DIFFRACTION (1.8 Å)